Trial Profile
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Pazopanib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 29 Mar 2017 Status changed to discontinued due to slow accrual
- 24 May 2016 Status changed from discontinued to completed.
- 08 May 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.